We're joined today by Dr. Aaron Goodman, a hematologist/oncologist at the University of California San Diego, to discuss diffuse large B-cell lymphoma (DLBCL). We talk about bad cancer drugs and bad Twitter users.

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.84 DLBCL, Bad Cancer Drugs and Bad Twitter Users with Dr. Aaron Goodman

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.84 DLBCL, Bad Cancer Drugs and Bad Twitter Users with Dr. Aaron Goodman

Download our free app to listen on your phone